A phase I trial of allogeneic tumour-activated natural killer lymphocytes after low dose TBI and fludarabine for the treatment of selected patients with acute myeloid leukaemia.

niversity College London0 个研究点目标入组 15 人开始时间: 2014年12月17日最近更新: 2019年3月25日

适应症

试验速览

•All recipients will have a diagnosis of acute myeloid leukaemia (AML) and be in one of the following subgroups:
•1. Patients aged > 60 years in PR (blasts >5<20% in BM) after 2nd course of induction chemotherapy
•2. Patients aged > 60 years with relapsed AML in CR2 after re-induction chemotherapy
•3. Patients aged > 60 years in PR or CR after 2 courses of chemotherapy with poor risk disease using standard MRC criteria
•4. Patients aged < 60 years beyond CR2 who are not suitable for stem cell transplantation with conventional or reduced intensity conditioning protocols

•1. HIV 1-2 seropositive
•2. Psychiatric, addictive, or any disorder which compromises ability to give true informed consent for participation in this study
•3. Pregnant or lactating women
•4. Patients whose life expectancy is severely limited by illness other than for which they are undergoing immunotherapy
•5. Patients with other active malignancy
•6. Patients with known physical or religious sensitivity or prior exposure to murine and/or ovine proteins

发起方

niversity College London